Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(10)60129-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Early Recurrence of Triple Negative Breast Cancer with Pathological Complete Response Following Neoadjuvant Chemotherapy and a Poor Prognosis-A Case Report].
Gan To Kagaku Ryoho
December 2024
Breast Center, Kochi Medical School Hospital.
In this study, we report the case of a patient with triple-negative breast cancer who achieved a pathological complete response(pCR)following neoadjuvant chemotherapy but experienced early recurrence and had a poor prognosis. A 46-year-old woman with a diagnosis of triple-negative breast cancer(cT2cN3cM0, cStage ⅢC)received neoadjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide, followed by weekly paclitaxel. The patient underwent a mastectomy and axillary lymph node dissection, achieving pCR.
View Article and Find Full Text PDFClinicopathological factors affecting response and survival in stage III breast cancer patients undergoing a dose-dense neoadjuvant regimen.
Clin Ter
November 2024
Department of Physiology, Hanoi Medical University, Hanoi, Vietnam.
Introduction: Identifying predictors of pathological complete response (pCR) and long-term outcomes after neoadjuvant treatment for breast cancer is needed to individualize treatment and patient monitoring. This study aimed to investigate clinicopathological factors affecting pCR and long-term outcomes in stage III breast cancer patients receiving a dose-dense neoadjuvant regimen.
Methods: This is a retrospective study including patients with stage III breast cancer who received neoadjuvant chemotherapy consisting of doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m², followed by paclitaxel 175 mg/m² every two weeks at Vietnam National Cancer Hospital and Hanoi Oncology Hospital between January 2015 and December 2022.
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.
J Immunother Cancer
November 2024
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
Background: Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30-40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs).
View Article and Find Full Text PDFImmunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
Gynecol Oncol
December 2024
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan. Electronic address:
Background: The iPocc trial, a randomized, global phase 3 study that compared intraperitoneal (IP) and intravenous (IV) carboplatin with dose-dense paclitaxel chemotherapy in epithelial ovarian cancer (EOC) patients, demonstrated improved progression-free survival in patients who received IP chemotherapy. The present study aimed to investigate the role of preexisting tumor immunity in the clinical outcomes of patients receiving IP chemotherapy.
Methods: This study involved analyzing patient data from the iPocc trial, selectively of those whose tumor specimens were preserved at the time of primary surgery.
Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.
Cancers (Basel)
September 2024
German Breast Group, 63263 Neu-Isenburg, Germany.
Article Synopsis
- Neoadjuvant systemic therapy (NST) is gaining importance in breast cancer treatment as it helps downstage tumors and provides insights into therapy responses, impacting individual prognoses and treatment choices.
- Common NST regimens include anthracyclines and taxanes, with specific recommendations for HER2-positive and triple-negative breast cancer patients to enhance outcomes.
- Recent clinical trials are focusing on optimizing NST options, especially for high-risk breast cancer, with emerging strategies like immune checkpoint inhibitors showing potential benefits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!